According to the newest data from Global Bipolar CohortOnly 29% of individuals with bipolar disorder are prescribed lithium. Despite being the “gold standard” for treating this mental health condition, we regularly prioritize concepts over scientific fact, and ignore one of the best available treatments.
Lithium just isn’t a posh molecule synthesized in a classy laboratory. It is barely one element, the third within the periodic table, and since Australian psychiatrist John Cade discovered its therapeutic properties in 1949, it has maintained a relevance that no other psychotropic drug has matched.
This longevity just isn’t a relic of the past but a mirrored image of its clinical strength. Despite a long time of research and the continual emergence of recent medications, no alternative has shown comparable efficacy within the long-term prevention of manic and depressive episodes in bipolar disorder.
According to 1 Review published in 2024.lithium continues to be “the primary treatment for mood disorders in general and in bipolar disorder in particular”. It can be the usual against which all other treatment options are compared, each for stabilizing mood and reducing the chance of relapse.
It is the one mood stabilizer with proven efficacy in treating mania and depression in addition to stopping relapse. Additionally, recent studies confirm that it can also have neuroprotective properties, from modulation of cellular pathways involved in neural plasticity to potential effects in stopping mild cognitive impairment and dementia.
These properties explain why international guidelines still rank it as a first-line treatment for bipolar disorder. The consensus was published in 2025. stated that it needs to be prescribed more steadily, contrary to the unfounded concerns that also persist in clinical practice.
Reduction in suicide
Above all, there’s one aspect that sets lithium other than other psychopharmaceutical drugs: its ability to cut back the chance of suicide. No other drug has demonstrated such a consistent protective effect.
Oh 2024 review highlighted that, despite methodological difficulties in studying this statistically rare event, the body of evidence from clinical trials, observational studies and meta-analyses all points in the identical direction: lithium reduces mortality and suicide attempts.
This is probably going resulting from its ability to cut back arousal, stabilize extreme mood swings, and forestall relapses of depression, all of which create moments of biggest vulnerability.
Beyond episodic treatment
Current research can be lithium’s ability to change the course of bipolar disorder. Not only does it prevent episodes, it also protects the brain, and evidence suggests that, unlike some antipsychotics, it improves brain communication and preserves verbal fluency.
In fact, there are very interesting statistics that suggest this. May reduce the risk of dementia. as much as 50%. Even residual levels in drinking water are visible. Protective effect At the population level. Lithium, in brief, is a molecule with extraordinary neuroprotective potential.
But the neuroprotective effects don’t stop there. Recent studies also suggest that lithium stimulates production. Brain-derived neurotrophic factorA protein essential for neuronal survival and development that is commonly deficient in patients with bipolar disorder.
In other words, it doesn’t just prevent the brain from getting damaged — it actively helps repair it.
Blood Monitoring and ‘Healthy Medicine’
It is commonly argued that the necessity for blood tests to watch lithium levels (the utmost therapeutic range is 0.6-0.8 mmol/L) is an inconvenience. However, from a strictly clinical standpoint, This monitoring is a protection, not a threat.. This is what allows dosage to be adjusted to every patient’s exact biology, a type of “precision medicine” that we were practicing long before the term became fashionable.
We also needs to note that many commonly used drugs—from anticoagulants to immunosuppressants—require the identical form of laboratory monitoring, yet usually are not considered dangerous for that reason.
Lithium management requires not fear but rigor. So why is it less often really useful? The answer is complicated. This is partly resulting from pressure from the pharmaceutical industry to develop latest, patentable molecules – lithium, being a natural element, can’t be patented. There can be a level of clinical reluctance resulting from its narrow therapeutic window – it must be rigorously controlled to make sure a secure but effective dose.
However, international guidelines are clear: lithium needs to be the primary alternative. We cannot ignore it in favor of less efficient alternatives because they seem more modern. This form of error shouldn’t affect clinical practice.
Newer is not all the time higher.
Good psychopharmacology just isn’t an issue of chasing the newest advances, but of using essentially the most appropriate treatment for every individual at each stage of their illness.
Lithium has a proven track record spanning a long time, in areas that no other mood stabilizer can concurrently address. It controls manic and depressive episodes, prevents suicide, and provides functional neuroprotection. Three regions, in a single medicine.
That doesn’t suggest it’s right for everybody. Good psychopharmacology should all the time keep off against delusion and belief alike, but abandoning lithium use without ever seriously considering it deprives patients of an option that, based on the evidence, is clearly one of the best treatment option.
Our challenge today just isn’t to reinvent the wheel, but to know how best to make use of the therapeutic tools we have already got. A drug doesn’t change into obsolete simply because time has passed. It becomes obsolete when latest evidence emerges and replaces it. In the case of lithium, latest evidence only confirms its value.